{"id":"dexlansoprazole-mr-qd","safety":{"commonSideEffects":[{"rate":"12-15","effect":"Headache"},{"rate":"8-12","effect":"Diarrhea"},{"rate":"5-8","effect":"Abdominal pain"},{"rate":"4-7","effect":"Nausea"},{"rate":"3-5","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexlansoprazole is the active R-enantiomer of lansoprazole, a proton pump inhibitor (PPI). It binds to and inactivates the hydrogen-potassium adenosine triphosphatase (H+/K+-ATPase) pump on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. The modified-release (MR) formulation provides dual-peak plasma concentrations to maintain acid suppression throughout the day with once-daily dosing.","oneSentence":"Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:50.988Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Healing of erosive esophagitis"},{"name":"Maintenance of healed erosive esophagitis"}]},"trialDetails":[{"nctId":"NCT03829150","phase":"NA","title":"Dexlansoprazole MR-Based Concomitant Quadruple Therapy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2017-03-01","conditions":"Helicobacter Pylori Infection","enrollment":202},{"nctId":"NCT00255190","phase":"PHASE3","title":"Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-01","conditions":"Gastroesophageal Reflux Disease","enrollment":591},{"nctId":"NCT00321737","phase":"PHASE3","title":"Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Esophagitis, Reflux, Esophagitis, Peptic","enrollment":445},{"nctId":"NCT00251693","phase":"PHASE3","title":"Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-12","conditions":"Esophagitis, Reflux, Esophagitis, Peptic","enrollment":2038},{"nctId":"NCT00255151","phase":"PHASE3","title":"Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-01","conditions":"Esophagitis, Reflux, Esophagitis, Peptic","enrollment":451},{"nctId":"NCT00847808","phase":"PHASE3","title":"Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Gastroesophageal Reflux","enrollment":178},{"nctId":"NCT00251719","phase":"PHASE3","title":"Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-12","conditions":"Esophagitis, Reflux, Esophagitis, Peptic","enrollment":2054},{"nctId":"NCT00255164","phase":"PHASE3","title":"Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-01","conditions":"Esophagitis, Reflux, Esophagitis, Peptic","enrollment":451},{"nctId":"NCT00847210","phase":"PHASE1","title":"Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-05","conditions":"Gastroesophageal Reflux","enrollment":36},{"nctId":"NCT00321984","phase":"PHASE3","title":"Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-06","conditions":"Gastroesophageal Reflux Disease","enrollment":947},{"nctId":"NCT00251745","phase":"PHASE3","title":"Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-12","conditions":"Gastroesophageal Reflux Disease","enrollment":908},{"nctId":"NCT00251758","phase":"PHASE3","title":"Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-12","conditions":"Gastroesophageal Reflux Disease","enrollment":908}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAK-390","T-168390","TAK-390MR","Kapidex","Dexilant"],"phase":"phase_3","status":"active","brandName":"Dexlansoprazole MR QD","genericName":"Dexlansoprazole MR QD","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells. Used for Gastroesophageal reflux disease (GERD), Healing of erosive esophagitis, Maintenance of healed erosive esophagitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}